HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 243 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,210 | +4.3% | 24,676 | -0.8% | 0.05% | +13.6% |
| Q2 2023 | $2,118 | -3.3% | 24,876 | -6.0% | 0.04% | -6.4% |
| Q1 2023 | $2,191 | +5.2% | 26,476 | 0.0% | 0.05% | 0.0% |
| Q4 2022 | $2,082 | -99.9% | 26,476 | +2.7% | 0.05% | +2.2% |
| Q3 2022 | $1,908,000 | +50.2% | 25,780 | +32.3% | 0.05% | +58.6% |
| Q2 2022 | $1,270,000 | +3.1% | 19,480 | 0.0% | 0.03% | +20.8% |
| Q1 2022 | $1,232,000 | -15.5% | 19,480 | -29.1% | 0.02% | 0.0% |
| Q4 2021 | $1,458,000 | -24.8% | 27,480 | 0.0% | 0.02% | -31.4% |
| Q3 2021 | $1,940,000 | +6.0% | 27,480 | 0.0% | 0.04% | +9.4% |
| Q2 2021 | $1,831,000 | -2.3% | 27,480 | +62.8% | 0.03% | +3.2% |
| Q1 2021 | $1,874,000 | -0.7% | 16,880 | +6.2% | 0.03% | -11.4% |
| Q4 2020 | $1,888,000 | +52.4% | 15,900 | +12.0% | 0.04% | +29.6% |
| Q3 2020 | $1,239,000 | +34.4% | 14,200 | +37.9% | 0.03% | +28.6% |
| Q2 2020 | $922,000 | +71.4% | 10,300 | +90.7% | 0.02% | +40.0% |
| Q1 2020 | $538,000 | – | 5,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |